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791Abstracts
OBJECTIVES: To characterize patients suffering from restless
legs syndrome (RLS) and assess their annual health care
resources consumption in comparison with a population of
average ambulatory patients seen by General Practitioners (GPs),
in France. METHODS: This study was based on anonymous
individual longitudinal medical records of adult patients suffer-
ing from RLS provided by physicians from a permanent panel of
representative French GPs. RLS was deﬁned accordingly to
established diagnostic criteria. Patients with at least one com-
plaint of legs and/or sleep symptoms suggestive of RLS in 2003
were included. Data about patients’ socio-demographic charac-
teristics, clinical status, medical resources consumption and sick
leaves over one year were collected retrospectively. For the cost
comparison, RLS patients were matched for sex and age to a cor-
responding random population of patients followed by the same
GPs. Average annual costs in € were estimated from the per-
spective of Health Insurance. RESULTS: A total of 515 RLS
patients were included. Mean age was 63.8 years and 76% were
female. 14% of patients had both complaints of leg and sleep
symptoms, 59% only leg troubles and 27% only sleep distur-
bances. All together, RLS patients consumed signiﬁcantly (p <
0.0001) more health care resources than those from the com-
parison group. On average in 2003, they saw 11.6 times their
GPs (versus 4.6 in the comparison group), 7 investigations were
prescribed (versus 4.3) and they had had 46.8 drug prescriptions
(versus 16.5). The mean annual medical cost of RLS patients’
follow-up by GPs was twice higher than that of average con-
sulting patients (840€ versus 391€, p < 0.0001). CONCLU-
SIONS: This study shows that patients satisfying to validated
diagnostic criteria consumed signiﬁcantly more medical
resources than “ordinary” patients in primary care bearing in
mind that RLS remains an unknown and under-diagnosed con-
dition. This population deserves thus a special attention in order
to optimize the treatment.
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OBJECTIVES: Idiopathic RLS (Ekbom syndrome) is a sensori-
motor disorder that leads to disrupted sleep and poor quality of
life. Until now, there have been no internationally approved
treatments for this disorder. This study evaluated costs and out-
comes resulting from the use of ropinirole in patients with RLS.
METHODS: Data were combined from 553 patients enrolled in
two matching, pivotal, randomized, 12-week, double-blind,
placebo-controlled studies. Patients with moderate-to-severe
RLS received ropinirole or placebo, with a maximum allowable
dose of 4mg/day. The primary outcome measure was the Inter-
national Restless Legs Scale (IRLS). IRLS scores at baseline and
study endpoint were mapped to the multi-attribute utility instru-
ment EQ-5D based on expert opinion to derive Quality-Adjusted
Life Years (QALYs). Costs of study drug, concomitant neuro-
logical medications and cost of adverse events were applied in
the model from the perspective of the UK NHS. Lower cost per
QALY gained indicates better cost-effectiveness. RESULTS:
Based on combined analysis of the entire treatment population
over 12 weeks, the QALYs gained for ropinirole and placebo
were 0.095 (0.082–0.106) and 0.075 (0.063–0.086), respec-
tively. The mean costs per patient for ropinirole and placebo
were £210.52 (£197–£223) and £42.34 (£34–£53), respectively.
The incremental QALYs and costs were 0.020 (0.002–0.037) and
£168.18 (£150–£187), respectively, resulting in an incremental
cost per QALY of £8405 (£4557–£41,524). Extrapolation of
IRLS scores at trial endpoint to 52 weeks improved the incre-
mental QALY to £6748. For patients reporting more severe sleep
disturbance or more severe symptoms at baseline, the cost-effec-
tiveness ratios improved to £5810 (£3210–£20,177) and £4587
(£2881–£10,508), respectively. CONCLUSIONS: In the absence
of an active-treatment comparator, this analysis found that treat-
ment of moderate-to-severe RLS with ropinirole is cost-effective
compared with placebo using conventional UK cost-effectiveness
standards, particularly in patients with more severe sleep distur-
bance and severe RLS symptoms at baseline.
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OBJECTIVE: Assess utilization of Dysport and BOTOX for cer-
vical dystonia and blepharospasm and compute the cost conse-
quences of toxin selection. METHODS: Six European study sites
abstracted drug utilization data from the records of their patients
who had received Dysport then BOTOX or BOTOX then
Dysport in a drug crossover that occurred in clinical practice. To
reduce potential selection bias and confounding variables,
patient records were screened for study inclusion/exclusion cri-
teria during scheduled clinic visits. Patients were screen-qualiﬁed
if they were 18 years of age, medically stable, responsive to per-
sistent toxin therapy for 1 year before and after drug crossover,
did not receive other medications that affect neuromuscular
transmission, and were not involved in another drug study.
RESULTS: A total of 132 screen-qualiﬁed patients were assessed.
Ratios of mean dose (units) Dysport: BOTOX ranged from 2 :1
to 11 :1, with 88% of patients greater than or equal to 3 :1,
regardless of study site or direction of drug crossover. When
current UK pricing for BOTOX and Dysport is applied to dis-
tribution of ratios, patients started on Dysport and switched to
BOTOX (N = 94) result in an incremental net savings of £1572.4
or an average savings of £16.7 per patient. When patients were
started on BOTOX and switched to Dysport (N = 38), an incre-
mental net cost of £252.9 or an average cost of £6.7 per patient
is realized. CONCLUSION: BOTOX utilization likely leads to
net cost savings compared with Dysport based on utilization and
current pricing for the UK.
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OBJECTIVES: To compare the costs of PD when using rasagi-
line and entacapone to treat patients that experienced motor ﬂuc-
tuations. METHODS: An 18-week randomised double-blind
controlled clinical trial (RCT) LARGO, evaluating the safety and
efﬁcacy of rasagiline 1mg/d, entacapone 200mg with levodopa
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